TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial
Brief Summary: The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA | Arm Label: group 2; Type: EXPERIMENTAL; Interventions: Drug: rt-PA | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: rt-PA; Assigned to Arm(s): group 2
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2
D: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis--The ATTRACT Trial
Brief Summary: The purpose of this study is to determine if the use of adjunctive Pharmacomechanical Catheter Directed Thrombolysis, which includes the intrathrombus administration of rt-PA--Activase (Alteplase),can prevent the post-thrombotic syndrome(PTS)in patients with symptomatic proximal deep vein thrombosis(DVT)as compared with optimal standard DVT therapy alone.


Options:
A: N/A
B: Arm Label: rIVCF; Type: EXPERIMENTAL; Interventions: Device: Cook 'Celect' retrievable inferior vena cava filter | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cook 'Celect' retrievable inferior vena cava filter; Assigned to Arm(s): rIVCF
C: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: ALN optional filter | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: ALN optional filter; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Brief Summary: This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study of RAD0001 in the Treatment of Angiomyolipoma in Patients With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
Brief Summary: This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
C: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
D: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Weight and Diabetes Risk in an Underserved Population
Brief Summary: The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications. We will examine the effectiveness of the intervention in

1. reducing weight and Body Mass Index;
2. reducing fasting insulin levels and increasing insulin sensitivity; and
3. reducing total cholesterol and LDL cholesterol.


Options:
A: Arm Label: Participants will take aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Participants will take risperidone; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Participants will take aripiprazole | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Participants will take risperidone
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine versus risperidone | Intervention Type: DRUG; Name: olanzapine versus risperidone; Assigned to Arm(s): 1, 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Premier Lifestyle Intervention with DASH Diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Premier Lifestyle Intervention with DASH Diet; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Weight and Diabetes Risk in an Underserved Population
Brief Summary: The purpose of this study is to examine the effectiveness of a lifestyle intervention designed to reduce weight and diabetes risk in a population of individuals with mental illness who are also taking antipsychotic medications. We will examine the effectiveness of the intervention in

1. reducing weight and Body Mass Index;
2. reducing fasting insulin levels and increasing insulin sensitivity; and
3. reducing total cholesterol and LDL cholesterol.


Options:
A: Arm Label: Enhanced treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced treatment as usual plus adherence training | Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced treatment as usual plus CBT-AD | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus adherence training; Assigned to Arm(s): Enhanced treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced treatment as usual plus CBT-AD; Assigned to Arm(s): CBT-AD
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Premier Lifestyle Intervention with DASH Diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Premier Lifestyle Intervention with DASH Diet; Assigned to Arm(s): 1
C: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: diabetes self management support; Type: ACTIVE_COMPARATOR; Interventions: Other: diabetes self management support | Intervention Type: OTHER; Name: diabetes self management support; Assigned to Arm(s): diabetes self management support
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Brief Summary: The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nurse Case Management intervention; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Education for diabetes self-management; Assigned to Arm(s): N/A
C: Arm Label: Transition Coordinator; Type: OTHER; Interventions: Other: Transition Coordinator | Arm Label: Current Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Transition Coordinator; Assigned to Arm(s): Transition Coordinator
D: Arm Label: ATO-SR; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Telephone Outreach with Speech Recognition | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Automated Telephone Outreach with Speech Recognition; Assigned to Arm(s): ATO-SR | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Automated Telephone Outreach With Speech Recognition to Improve Diabetes Care: A Randomized Controlled Study
Brief Summary: The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.


Options:
A: Arm Label: Computer Assisted Self Management plus Social Support; Type: EXPERIMENTAL; Interventions: Behavioral: CASM + | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Computer Assisted Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: CASM | Intervention Type: BEHAVIORAL; Name: CASM +; Assigned to Arm(s): Computer Assisted Self Management plus Social Support | Intervention Type: BEHAVIORAL; Name: CASM; Assigned to Arm(s): Computer Assisted Self Management
B: Arm Label: Automated Phone-Based Refill Reminders; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Phone-Based Refill Reminders | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Automated Phone-Based Refill Reminders; Assigned to Arm(s): Automated Phone-Based Refill Reminders
C: Arm Label: ATO-SR; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Telephone Outreach with Speech Recognition | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Automated Telephone Outreach with Speech Recognition; Assigned to Arm(s): ATO-SR | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
D: Arm Label: Reminder and Outreach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Reminder and Outreach Intervention | Arm Label: Usual Care Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder and Outreach Intervention; Assigned to Arm(s): Reminder and Outreach Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Brief Summary: RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Options:
A: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
B: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Brief Summary: RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Options:
A: Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management
B: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
Brief Summary: RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Options:
A: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: Nicotine Patch (4 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Nicotine Patch (8 weeks); Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Nicotine Patch (4 weeks), Nicotine Patch (8 weeks)
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm III; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm III | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: Nicotine patch plus placebo gum; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Placebo gum | Arm Label: Nicotine patch plus active gum; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavior Therapy for alcohol and smoking cessation, Drug: Nicoderm CQ nicotine patch, Drug: Nicotine gum - Nicorette® | Intervention Type: BEHAVIORAL; Name: Cognitive Behavior Therapy for alcohol and smoking cessation; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicoderm CQ nicotine patch; Assigned to Arm(s): Nicotine patch plus active gum, Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Placebo gum; Assigned to Arm(s): Nicotine patch plus placebo gum | Intervention Type: DRUG; Name: Nicotine gum - Nicorette®; Assigned to Arm(s): Nicotine patch plus active gum

Answer: C